Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 10:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 254 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Maximum Tolerated Dose Clear all

Conditions: Dyslipidemias, Hypercholesterolemia, Familial Hypercholesterolemia, ASCVD, High Cholesterol
Interventions: Combination Therapy, Monotherapy obicetrapib, Monotherapy ezetimibe, Combination Therapy placebo, Obicetrapib Placebo, Ezetimibe Placebo; Combination Product · Drug · Other
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 45
States / cities: Gilbert, Arizona • Jacksonville, Florida • Port Orange, Florida + 37 more

Conditions: Advanced Solid Tumors
Interventions: 2X-121 600 mg, 2X-121 800 mg, 2X-121 1000 mg, 2X-121 + 300 mg dovitinib, 2X-121 + 400 mg dovitinib, 2X-121 + 500 mg dovitinib; Drug · Combination Product
Lead sponsor: Allarity Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Huntersville, North Carolina • Cleveland, Ohio • Oklahoma City, Oklahoma

Conditions: Advanced Solid Tumor
Interventions: aldoxorubicin; Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Neoplasm Metastasis
Interventions: XMT-1107; Drug
Lead sponsor: Mersana Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 4
States / cities: Baltimore, Maryland • Boston, Massachusetts • Nashville, Tennessee

Conditions: Chronic Myelogenous Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Interventions: Asciminib (ABL001), Nilotinib, Imatinib, Dasatinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 6
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • New York, New York + 3 more

Conditions: Burn Injury
Interventions: SN514-066b; Biological
Lead sponsor: SERDA bv; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Sarcoma, Neuroblastoma, Wilms Tumor, Osteosarcoma, Brain Tumor
Interventions: Pazopanib (GW786034); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 25 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Lymphoma, Melanoma (Skin), Neoplastic Syndrome
Interventions: yttrium Y 90-edotreotide; Radiation
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2003
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Prostate Cancer
Interventions: Everolimus, Enzalutamide; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older · Male only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 5
States / cities: Fort Myers, Florida • St. Petersburg, Florida • Cincinnati, Ohio + 2 more

Conditions: Dose Escalation, Safety, Preliminary Efficacy, Advanced Solid Tumors, Metastatic Breast Cancer, Advanced Pancreatic Adenocarcinoma, Metastatic Colorectal Cancer, Recurrent Glioblastoma Multiforme, Gastric Cancer, Gastroesophageal Junction Cancer, Triple Negative Metastatic Breast Cancer, Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer
Interventions: LDE225, BKM120; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 13
States / cities: Los Angeles, California • San Francisco, California • Tampa, Florida + 9 more

Conditions: Breast Cancer, Hematologic Neoplasms
Interventions: AUY922 2 mg/m2; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 7
States / cities: Los Angeles, California • Augusta, Georgia • Boston, Massachusetts + 4 more

Conditions: Hodgkin's Lymphoma, Lymphoma, Non-Hodgkin
Interventions: Bortezomib, Ruxolitinib; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Schizophrenia
Interventions: NW-3509a; Drug
Lead sponsor: Newron Pharmaceuticals SPA; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Solid Tumor, Adult, Squamous Cell Carcinoma of Head and Neck, Colorectal Adenocarcinoma, Metastatic Solid Tumor, Recurrent Solid Tumor, Head and Neck Cancer
Interventions: NT219, NT219 and ERBITUX® - Dose Escalation, NT219 and ERBITUX® - Expansion; Drug
Lead sponsor: TyrNovo Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 7
States / cities: Encinitas, California • Los Angeles, California • San Diego, California + 4 more

Conditions: Multiple Myeloma
Interventions: CC-220, Dexamethasone, Daratumumab, Bortezomib, Carfilzomib, Daratumumab - 16mg/kg, Bortezomib (BTZ), Daratumumab- 1800mg; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 58
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Atlanta, Georgia + 24 more

Conditions: Recurrent Bladder Carcinoma, Bladder Cancer Stage 0, Bladder Cancer Stage I
Interventions: Pharmacokinetic Study, Recombinant EphB4-HSA Fusion Protein; Other · Biological
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Stage IV Non-small Cell Lung Cancer
Interventions: Belinostat, Carboplatin, Paclitaxel; Drug
Lead sponsor: Acrotech Biopharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 4
States / cities: Huntsville, Alabama • Santa Monica, California • Boynton Beach, Florida + 1 more

Conditions: Metastatic Solid Tumors, Esophageal Cancer, Non-Small Cell Lung Cancer
Interventions: M1231; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Houston, Texas • San Antonio, Texas

Conditions: Neoplasms
Interventions: RG1530; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 6
States / cities: Boston, Massachusetts • Detroit, Michigan • Las Vegas, Nevada + 1 more

Conditions: Colorectal Cancer, Gastro Esophageal Junctional Cancer, Gastric Cancer (GC), GEJ Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC), Gall Bladder Cancer, Cholangiocarcinoma
Interventions: IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody; Drug
Lead sponsor: Iksuda Therapeutics Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • Nashville, Tennessee + 1 more

Conditions: Colon Cancer, Rectal Cancer
Interventions: lenalidomide, cetuximab, mutation analysis, polymerase chain reaction, polymorphism analysis; Drug · Biological · Other + 1 more
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Postherpetic Neuralgia
Interventions: Retigabine, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 41
States / cities: Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 36 more

Conditions: Breast Neoplasm, Pancreatic Neoplasm, Lung Neoplasm, Ovarian Neoplasm, Renal Neoplasm
Interventions: TAK-165; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 4
States / cities: Scottsdale, Arizona • San Antonio, Texas

Conditions: Advanced Pancreatic Cancer, Advanced Solid Tumor
Interventions: Metformin, Simvastatin, Digoxin; Drug
Lead sponsor: Danae Hamouda, MD; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Toledo, Ohio

Search by objective public record fields.

Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies

Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patients With Advanced Solid Tumors

Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors

A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

SN514-066b Enzyme in Deep Partial Thickness Burns

A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma

A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.

A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer

MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC

M1231 in Participants With Solid Tumors

A Multiple Ascending Dose Study of R1530 in Patients With Advanced Solid Tumors.

IKS04 Regimen in Advanced Solid Tumors That Express CA242

Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer

Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)

Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2

Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors